- Home
- PDT vs ORIC Comparison
PDT vs ORIC Comparison
Compare PDT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDT
- ORIC
- Stock Information
- Founded
- PDT 1989
- ORIC 2014
- Country
- PDT United States
- ORIC United States
- Employees
- PDT N/A
- ORIC N/A
- Industry
- PDT Finance Companies
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PDT Finance
- ORIC Health Care
- Exchange
- PDT Nasdaq
- ORIC Nasdaq
- Market Cap
- PDT 636.9M
- ORIC 545.5M
- IPO Year
- PDT N/A
- ORIC 2020
- Fundamental
- Price
- PDT $13.03
- ORIC $5.53
- Analyst Decision
- PDT
- ORIC Strong Buy
- Analyst Count
- PDT 0
- ORIC 9
- Target Price
- PDT N/A
- ORIC $18.43
- AVG Volume (30 Days)
- PDT 145.6K
- ORIC 734.5K
- Earning Date
- PDT 01-01-0001
- ORIC 05-05-2025
- Dividend Yield
- PDT 8.88%
- ORIC N/A
- EPS Growth
- PDT N/A
- ORIC N/A
- EPS
- PDT N/A
- ORIC N/A
- Revenue
- PDT N/A
- ORIC N/A
- Revenue This Year
- PDT N/A
- ORIC N/A
- Revenue Next Year
- PDT N/A
- ORIC N/A
- P/E Ratio
- PDT N/A
- ORIC N/A
- Revenue Growth
- PDT N/A
- ORIC N/A
- 52 Week Low
- PDT $8.77
- ORIC $5.26
- 52 Week High
- PDT $13.05
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- PDT 57.88
- ORIC 30.08
- Support Level
- PDT $12.81
- ORIC $5.78
- Resistance Level
- PDT $13.12
- ORIC $8.11
- Average True Range (ATR)
- PDT 0.16
- ORIC 0.52
- MACD
- PDT 0.03
- ORIC -0.14
- Stochastic Oscillator
- PDT 85.94
- ORIC 9.57
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.